Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study.

ABSTRACT:

Background

Mycoplasma genitalium has a tendency to develop macrolide and quinolone resistance.

Objectives

We investigated the microbiological cure rate of a 7 day course of sitafloxacin for the treatment of rectal and urogenital infections in MSM.

Patients and methods

This open-label, prospective cohort study was conducted at the National Center for Global Health and Medicine, Tokyo, Japan from January 2019 to August 2022. Patients with M. genitalium urogenital or rectal infections were included. The patients were treated with sitafloxacin 200 mg daily for 7 days. M. genitalium isolates were tested for parC, gyrA and 23S rRNA resistance-associated mutations.

Results

In total, 180 patients (median age, 35 years) were included in this study, of whom 77.0% (97/126

SUBMITTER: Ando N 

PROVIDER: S-EPMC10393875 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature